MétaCan
Menu
Back to cohort
Record W4386470118 · doi:10.3389/fped.2023.1273639

Editorial: Modern approaches to hemophilia management in children and adolescents

2023· editorial· en· W4386470118 on OpenAlexaff
Ali Amid

Bibliographic record

VenueFrontiers in Pediatrics · 2023
Typeeditorial
Languageen
FieldMedicine
TopicHemophilia Treatment and Research
Canadian institutionsBC Children's HospitalUniversity of British Columbia
Fundersnot available
KeywordsMedicineHematologyPediatricsIntensive care medicineInternal medicine

Abstract

fetched live from OpenAlex

Editorial on the Research Topic Modern approaches to hemophilia management in children and adolescentsHemophilia A and B are the most common severe bleeding disorders which are due to partial or total deficiency of coagulation factor VIII (FVIII) or factor IX (FIX), respectively.Depending on the severity of coagulation factor deficiency, the affected individuals may experience bleeding only with severe trauma or during major surgery (mild hemophilia) to spontaneous hemarthrosis, hematomas, and intracranial hemorrhages in the absence of any identifiable trauma (severe hemophilia) (1).Until recently, coagulation factor replacement therapy via plasma-derived factor concentrates or recombinant factor products has been the mainstay of hemophilia treatment, provided either prophylactically or on-demand to treat bleeding episodes.Despite the widespread availability of safe and effective replacement therapy, many individuals with hemophilia continue to experience significant burden from their treatment, breakthrough bleeding, and debilitating arthropathy.In addition, the relatively high rate of inhibitor development to factor products can cause major morbidity and mortality, leading to a considerable burden on patients, families, and healthcare systems (2).Over the past two decades, however, there has been remarkable progress in the management of hemophilia.Cloning of the genes encoding factor VIII and factor IX, together with advances in bioengineering have led to novel therapies that offer easier modes of administration, extended half-lives, and improved patient outcomes and quality of life.In addition, gene therapy is under investigation as the next frontier in hemophilia treatment, especially for hemophilia B (3, 4).While these advances are associated with improvement of patients' outcomes, they also result in many new observations and questions that were not previously encountered.Furthermore, access to these treatments remains limited to the minority of people with hemophilia worldwide.In this Research Topic, Urasiski et al. review the Polish national experience of switching prophylaxis factor replacement therapy from standard-dose prophylaxis with a plasma-derived FVIII to recombinant FVIII in previously-treated patients (PTP), as the result of the national tender.Authors aimed to address two important questions: safety of switching from a plasmaderived product to a recombinant product, and the effectiveness of PK-tailored dosing vs. standard-dose approach.While the national tender mandated the switching of the products, children and adolescents had the choice of standard-dose or PK-tailored approach.Following the switch, no patient developed high-titer or persistent inhibitor (two patients had low-titer but transient inhibitors).Curiously, patients who chose standard-dose prophylaxis had a lower

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Editorial · Consensus signal: Editorial
Teacher disagreement score0.088
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0020.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.023
GPT teacher head0.269
Teacher spread0.245 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designNot applicable
Domainnot available
GenreEditorial

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueFrontiers in PediatricsSame topicHemophilia Treatment and ResearchFrench-language works237,207